In BRAF non-mutated metastatic melanoma, immune checkpoint inhibitors have been the standard of care since the approval of ipilimumab in March 2011 [8], pembrolizumab in September 2014 [9], and nivolumab in December 2014 as first-line therapies [10]. This evidence concerns the gene BRAF and metastatic melanoma.